ODAC rejects Marqibo

FDA's Oncologic Drugs Advisory Committee voted unanimously against accelerated approval for Marqibo vincristine from Inex (TSE:IEX) and Enzon (ENZN) to treat

Read the full 215 word article

User Sign In